sra-33 Antibody

What is IL-33 and what role do IL-33 antibodies play in research?

IL-33 is a broad-acting alarmin cytokine that drives inflammatory responses following tissue damage or infection. IL-33 antibodies are essential research tools that neutralize IL-33 activity in experimental systems. IL-33 exists in different forms including reduced IL-33 (IL-33red) and oxidized IL-33 (IL-33ox), each activating distinct signaling pathways. IL-33red signals through the ST2 receptor pathway, while IL-33ox can signal through the RAGE/EGFR complex pathway. IL-33 antibodies allow researchers to investigate these inflammatory mechanisms by specifically blocking IL-33 activity in various experimental systems .

How do I select appropriate anti-IL-33 antibodies for Western blotting applications?

When selecting anti-IL-33 antibodies for Western blotting, consideration of specificity and validated protocols is critical. Antibodies like the Recombinant Goat Anti-Human IL-33 Monoclonal Antibody have been validated to detect IL-33 at approximately 30 kDa under reducing conditions. For optimal results, use 1 μg/mL concentration followed by appropriate HRP-conjugated secondary antibodies. Always validate antibody performance in your specific cell or tissue system by including appropriate controls such as mock-transfected versus IL-33-transfected cell lysates. Additionally, adherence to standardized protocols with optimized buffer systems (e.g., Immunoblot Buffer Group 1) ensures consistent and reproducible results .

What are the diagnostic values of anti-Sa and anti-RA33 antibodies in rheumatoid arthritis research?

Meta-analysis data reveals that anti-Sa antibodies demonstrate 39.5% sensitivity (95% CI, 36.5–42.4) and 96.8% specificity (95% CI, 95.9–97.4) for rheumatoid arthritis (RA) diagnosis. In comparison, anti-RA33 antibodies show 31.8% sensitivity (95% CI, 28.7–35.0) and 90.1% specificity (95% CI, 87.8–92.1). The positive likelihood ratio (PLR) for anti-Sa antibody is 14.11 (95% CI, 7.076–28.13), making it particularly useful as a diagnostic marker. While both antibodies demonstrate high specificity, they lack sensitivity, suggesting their optimal use would be in conjunction with other RA biomarkers rather than as standalone diagnostic tools. Their high specificity makes them valuable for confirmation in research cohorts where definitive RA classification is essential .

What strategies can be employed to maintain IL-33 in its reduced form during experimental procedures?

Maintaining IL-33 in its reduced form (IL-33red) presents significant challenges due to its susceptibility to rapid oxidation. Researchers can employ several approaches to preserve IL-33red conformation and activity. One validated approach is to replace cysteine residues with serine to produce oxidation-resistant synthetic IL-33 (IL-33 C>S), which maintains ST2-dependent activity similar to IL-33red. During experimental procedures, minimize exposure to oxidizing conditions by using oxygen-depleted buffers supplemented with reducing agents. Alternatively, researchers can leverage antibodies like tozorakimab that bind IL-33red with high affinity and prevent its oxidation, effectively preserving its ST2-dependent signaling capabilities. This approach is particularly valuable for long-duration experiments where oxidation would otherwise compromise IL-33red-specific signaling pathway investigations .

How can contradictory data regarding IL-33-ST2 binding affinity be reconciled in experimental design?

The reported affinity of IL-33 for the ST2 receptor has varied by at least three orders of magnitude across published literature, creating challenges for experimental design. This discrepancy can be attributed to methodological differences, including immobilization of sST2, varying pH conditions, and the presence/absence of IL-1 receptor-accessory protein in binary complexes. To address this issue, researchers should implement high-sensitivity kinetic exclusion assays (KinExA) to measure affinity in free solution, which has established the IL-33–sST2 binding interaction at approximately 0.09 pM, among the highest affinity interactions reported. When designing competitive binding experiments, researchers must account for this exceptionally high affinity by ensuring antibody candidates demonstrate femtomolar affinity ranges. Experimental protocols should standardize conditions across laboratories and explicitly report all assay parameters to facilitate meaningful cross-study comparisons .

What are the optimal protocols for utilizing IL-33 antibodies in immunohistochemistry?

For optimal immunohistochemical detection of IL-33 in paraffin-embedded tissue sections, a systematic approach yields consistent results. Prepare tissues using immersion fixation followed by paraffin embedding. Section tissues at 5-7 μm thickness and perform antigen retrieval using citrate buffer (pH 6.0) prior to antibody incubation. For human tissues, use Recombinant Goat Anti-Human IL-33 Monoclonal Antibody at 0.3 μg/mL concentration with overnight incubation at 4°C. Visualization can be achieved using HRP-DAB staining systems with hematoxylin counterstaining. This protocol successfully detects IL-33 in nuclear localization patterns in human tonsil tissues. For other tissue types, optimization of antibody concentration and incubation time may be necessary. Always include appropriate isotype controls and positive control tissues with known IL-33 expression to validate staining specificity and minimize background .

How can researchers effectively measure IL-33 neutralization in cell-based assays?

Cell-based neutralization assays provide functional validation of anti-IL-33 antibody efficacy. A validated approach employs the D10.G4.1 mouse helper T cell line stimulated with recombinant human IL-33 in the presence of sub-optimal amounts of anti-CD3e antibody. Cell proliferation can be quantified using Resazurin or similar metabolic indicators to generate dose-response curves. To assess neutralization potency, introduce increasing concentrations of candidate anti-IL-33 antibodies and calculate neutralization dose (ND50) values. Effective antibodies like tozorakimab or MAB36254 typically demonstrate ND50 values of 0.75-3 μg/mL when neutralizing 12 ng/mL of recombinant human IL-33. This system offers advantages over simple binding assays by confirming functional neutralization and cellular relevance. Researchers should standardize IL-33 concentration, cell passage number, and incubation time to ensure reproducibility across experiments .

What approaches can be used to investigate the dual signaling pathways of IL-33 through both ST2 and RAGE/EGFR complexes?

Investigation of IL-33's dual signaling requires specialized methodologies to distinguish between ST2-dependent and RAGE/EGFR complex-dependent effects. For ST2-dependent signaling, measure canonical outputs including NF-κB activation, cytokine production (IL-4, IL-5, IL-13), and ST2-expressing cell proliferation. For RAGE/EGFR signaling, assess epithelial migration, wound healing, and activation of EGFR phosphorylation cascades. To differentiate these pathways experimentally, utilize specific inhibitors (ST2 blockers versus EGFR inhibitors) or siRNA-mediated knockdown of pathway components. Exploit the distinct responsiveness of IL-33red (primarily ST2) versus IL-33ox (primarily RAGE/EGFR) by controlling oxidation states through reducing/oxidizing conditions. Additionally, use cell systems that selectively express ST2 or RAGE/EGFR complexes. This approach enables comprehensive characterization of pathway-specific effects and clarifies the biological significance of IL-33's dual signaling capabilities in inflammation and tissue repair processes .

How should researchers design experiments to evaluate anti-IL-33 antibodies in acute lung injury models?

When designing acute lung injury models to evaluate anti-IL-33 antibodies, researchers should consider multiple factors to ensure robust and translatable results. First, establish baseline IL-33 release kinetics in your specific model, as epithelial injury typically causes rapid IL-33 release within minutes to hours. Pre-dose with anti-IL-33 antibodies at multiple timepoints (e.g., 24h, 12h, and 1h) before injury induction to determine optimal prophylactic timing. Alternatively, administer antibodies post-injury to assess therapeutic potential. Apply multiple doses of antibody to establish dose-response relationships, particularly focusing on doses that achieve serum concentrations exceeding IL-33's affinity for ST2. Monitor both immediate inflammatory responses (neutrophil infiltration, pro-inflammatory cytokines) and longer-term consequences (epithelial remodeling, fibrosis). Include appropriate controls such as isotype antibodies and soluble ST2 to distinguish antibody-specific effects from Fc-mediated or ST2-decoy effects. This comprehensive approach enables assessment of both ST2-dependent inflammatory responses and RAGE/EGFR-dependent epithelial repair mechanisms affected by IL-33 blockade .

What techniques can be employed to distinguish between effects of anti-IL-33 antibodies on reduced versus oxidized IL-33?

Distinguishing between effects on IL-33red versus IL-33ox requires specialized experimental approaches. First, generate both forms under controlled conditions: maintain IL-33red by using reducing agents (DTT or β-mercaptoethanol) and prepare IL-33ox by deliberate exposure to oxidizing conditions (H2O2 or atmospheric oxygen). Confirm oxidation status through mobility shift assays or redox-sensitive dyes. To assess antibody effects, pre-incubate either IL-33red or IL-33ox with candidate antibodies before adding to experimental systems. For functional validation, use cell types that predominantly express either ST2 (T cells, ILC2s) or RAGE/EGFR (epithelial cells) to separate pathway-specific responses. Measure ST2-dependent endpoints (IL-5/IL-13 production) and RAGE/EGFR-dependent endpoints (epithelial migration) in parallel. Additionally, implement time-course studies to capture the prevention of IL-33red oxidation by protective antibodies like tozorakimab. These approaches collectively enable clear differentiation between antibody effects on each IL-33 form and their respective signaling pathways .

What considerations are important when developing high-affinity antibodies against IL-33 for research applications?

Developing high-affinity IL-33 antibodies for research requires attention to several critical factors. First, antibody affinity must exceed that of IL-33 for ST2 (approximately 0.09 pM) to effectively compete for binding. Target association rates (kon) above 10^7 M^-1s^-1 to neutralize rapid IL-33 release events efficiently. During antibody generation, preserve conformational epitopes of IL-33red by using oxidation-resistant IL-33 C>S constructs where cysteine residues are replaced with serine. Implement comprehensive affinity maturation through CDR mutagenesis targeting all six complementarity-determining regions, as demonstrated in tozorakimab development where multiple amino acid changes across CDRs were required to achieve femtomolar affinity. Screen candidates using both binding competition and functional neutralization assays to ensure correlation between affinity and biological activity. Finally, validate antibody performance across multiple species if cross-reactivity is desired for translational research. This systematic approach enables development of research-grade antibodies with exceptional performance characteristics for investigating IL-33 biology .